Free Trial

InterCure (INCR) Competitors

InterCure logo
$1.48 +0.01 (+0.68%)
Closing price 07/1/2025 03:48 PM Eastern
Extended Trading
$1.40 -0.08 (-5.07%)
As of 07/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INCR vs. ADCT, TRDA, CRVS, ALLO, SGMT, TSVT, CDTX, FHTX, ANNX, and AMRN

Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include ADC Therapeutics (ADCT), Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), Allogene Therapeutics (ALLO), Sagimet Biosciences (SGMT), 2seventy bio (TSVT), Cidara Therapeutics (CDTX), Foghorn Therapeutics (FHTX), Annexon (ANNX), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

InterCure vs. Its Competitors

ADC Therapeutics (NYSE:ADCT) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

ADC Therapeutics currently has a consensus target price of $7.75, indicating a potential upside of 187.04%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe ADC Therapeutics is more favorable than InterCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ADC Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
InterCure
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

InterCure has a net margin of 0.00% compared to ADC Therapeutics' net margin of -197.64%.

Company Net Margins Return on Equity Return on Assets
ADC Therapeutics-197.64% N/A -45.57%
InterCure N/A N/A N/A

In the previous week, InterCure had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 3 mentions for InterCure and 2 mentions for ADC Therapeutics. InterCure's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.00 indicating that InterCure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ADC Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
InterCure
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

InterCure has lower revenue, but higher earnings than ADC Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ADC Therapeutics$70.84M3.78-$157.85M-$1.45-1.86
InterCure$64.55M1.04-$18.32MN/AN/A

41.1% of ADC Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ADC Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Summary

ADC Therapeutics beats InterCure on 8 of the 13 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INCR vs. The Competition

MetricInterCureMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$66.99M$10.48B$5.48B$8.94B
Dividend YieldN/A2.11%5.38%4.12%
P/E RatioN/A17.2326.2219.74
Price / Sales1.0426.99394.92109.12
Price / CashN/A22.8736.4957.06
Price / Book0.633.657.915.37
Net Income-$18.32M$233.36M$3.15B$248.34M
7 Day PerformanceN/A1.08%0.75%1.67%
1 Month Performance-6.92%3.06%3.46%4.56%
1 Year Performance-27.80%-11.71%34.60%18.42%

InterCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INCR
InterCure
0.8986 of 5 stars
$1.48
+0.7%
N/A-27.1%$66.99M$64.55M0.00350
ADCT
ADC Therapeutics
1.6598 of 5 stars
$2.68
-3.2%
$7.75
+189.2%
-26.6%$274.72M$75.82M-1.85310
TRDA
Entrada Therapeutics
3.4033 of 5 stars
$7.04
-1.1%
$25.67
+264.6%
-50.3%$270.23M$210.78M8.69110Trending News
Insider Trade
CRVS
Corvus Pharmaceuticals
2.9683 of 5 stars
$3.73
-5.8%
$15.00
+302.1%
+108.6%$269.95MN/A-3.8130Positive News
Insider Trade
ALLO
Allogene Therapeutics
3.4021 of 5 stars
$1.22
-0.8%
$8.44
+592.2%
-49.4%$269.04M$20K-0.99310
SGMT
Sagimet Biosciences
2.5044 of 5 stars
$8.36
-4.1%
$23.17
+177.1%
+154.1%$267.48M$2M-4.758
TSVT
2seventy bio
N/A$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
CDTX
Cidara Therapeutics
4.1229 of 5 stars
$44.95
+113.8%
$45.43
+1.1%
+307.2%$263.73M$1.27M-1.5390Trending News
Analyst Forecast
Insider Trade
High Trading Volume
FHTX
Foghorn Therapeutics
2.1077 of 5 stars
$4.89
+3.6%
$12.13
+148.0%
-16.6%$263.10M$23.50M-3.60120News Coverage
Positive News
ANNX
Annexon
2.8137 of 5 stars
$2.38
flat
$12.50
+425.2%
-51.1%$261.12MN/A-2.0260News Coverage
Positive News
AMRN
Amarin
0.7374 of 5 stars
$12.60
+0.5%
$7.00
-44.4%
+22.5%$259.67M$214.11M-3.46360

Related Companies and Tools


This page (NASDAQ:INCR) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners